GlassScriptPhysician profile
Melissa Winterhalter
NPI 1316072820
$1,838.93
in general payments reported to CMS, 2019-2025
24 companies · $206 in 2025
The $206 reported for 2025 was more than what 75% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.85 · 2020: $97.20 · 2021: $130 · 2022: $416 · 2023: $307 · 2024: $659 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,171.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $545.64 | 2022-2025 | Qelbree |
| Sanofi Pasteur INC. | $256.41 | 2021-2024 | |
| Kaleo, INC. | $186.43 | 2020-2023 | Auvi-Q |
| Corium, LLC | $139.93 | 2022-2025 | Azstarys |
| Merck Sharp & Dohme LLC | $111.11 | 2022-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Cranial Technologies, INC | $98.18 | 2020-2025 | Doc Band |
| Glaxosmithkline, LLC. | $81.20 | 2022-2023 | Bexsero |
| Tris Pharma INC | $52.21 | 2020-2024 | Dyanavel Xr |
| Alk-Abello, INC | $51.44 | 2025 | Neffy, Odactra, Grastek |
| Neos Therapeutics, LP | $39.39 | 2020-2024 | Adzenys Xr-Odt |
| Ars Pharmaceuticals Operations, INC. | $35.64 | 2025 | Neffy |
| Ironshore Pharmaceuticals INC. | $32.70 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.00 | 2021-2022 | |
| Neurelis, INC. | $22.65 | 2025 | Valtoco |
| Sobi, INC | $19.22 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $17.05 | 2024 | Flumist Quadrivalent |
| Nestle Healthcare Nutrition INC. | $17.04 | 2023 | |
| Covis Pharma Gmbh | $16.77 | 2020 | |
| Biomarin Pharmaceutical INC. | $16.71 | 2025 | Voxzogo 1.2mg |
| Adlon Therapeutics L.P. | $15.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.86 | 2025 | Zoryve |
| Pfizer INC. | $14.86 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.95 | 2024 | |
| Allergan, INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Winterhalter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.